Behfar A, Terzic A, Perez-Terzic CM: Regenerative principles enrich cardiac rehabilitation practice. Am J Phys Med Rehabil 2014;93(Suppl):S169YS175. Cardiovascular morbidity imposes a high degree of disability and mortality, with limited therapeutic options available in end-stage disease. Integral to standard of care, cardiac rehabilitation aims on improving quality-of-life and prolonging survival. The recent advent of regenerative technologies paves the way for a transformative era in rehabilitation medicine whereby, beyond controlling risk factors and disease progression, the prospect of curative solutions is increasingly tangible. To date, the spectrum of clinical experience in cardiac regenerative medicine relies on stem cellYbased therapies delivered to the diseased myocardium either acutely/subacutely, after a coronary event, or in the setting of chronic heart failure. Application of autologous/allogeneic stem cell platforms has established safety and feasibility, with encouraging signals of efficacy. Newer protocols aim to purify cell populations in an attempt to eliminate nonregenerative and enrich for regenerative cell types before use. Most advanced technologies have been developed to isolate resident cell populations directly from the heart or, alternatively, condition cells from noncardiac sources to attain a disease-targeted lineage-specified phenotype for optimized outcome. Because a multiplicity of cell-based technologies has undergone phase I/II evaluation, pivotal trials are currently underway in larger patient populations. Translation of regenerative principles into clinical practice will increasingly involve rehabilitation providers across the continuum of patient care. Regenerative rehabilitation is thus an emerging multidisciplinary field, full of opportunities and ready to be explored.
patients with disability, extending thereby the reach of traditional rehabilitation. Addressing unmet needs, implementation of regenerative medicine paradigms drives a major innovation in modern patient management. 1 A case in point is the anticipated impact of regenerative medicine in the context of cardiovascular disease, the leading cause of global morbidity and mortality. 2 In conjunction with rehabilitation programs, pharmacologic therapies have shown significant clinical and mortality benefit with impact on disease progression and quality-of-life. 3Y5 Furthermore, individuals who have progressive heart disease attain benefit from electrical resynchronization, as afforded by biventricular pacing, or augmented cardiac output with implantation of a left ventricular (LV) assist device. 6Y8 However, current standard of care falls short in reversing the course of disease. Because the only definitive treatment of end-stage heart disease is transplantation, regenerative biotherapies are of significant interest as a potential new way of addressing the treatment of patients with limited options.
During the last decade, regenerative medicine applied to cardiovascular disease has increasingly gained significant interest. Careful design and execution of clinical trials have demonstrated a favorable safety profile and documented feasibility of delivering stem cellYbased therapy. 9 Although initial efficacy data have shown rather limited signs of clinical benefit, the significant need for curative therapies in cardiovascular medicine has continued to drive innovation and refinement of cell-based technologies. 10Y12 Initially envisioned as a standalone technology, most recently, stem cellYbased therapies have been assessed for their ability to add to the benefit attained with standard of care. In this regard, cardiovascular regeneration has focused on two main avenues, namely, protection of the heart muscle at the time of injury (e.g., acute myocardial infarction) and regeneration of damaged or scarred myocardium in the chronically injured/failing heart. 13 Here, the authors provide an overview of clinical trials using various iterations of stem cell platforms, including the most recent progress in optimizing stem cellYbased technology. Furthermore, the authors will look at the role of cardiac rehabilitation, specifically exercise therapy, as a partner therapy to stem cellYbased regeneration and highlight the evolution of regenerative medicine from a cell-centric platform to one with the potential to engage a community of multispecialty practice.
FIGURE 1
Differences in harvest, processing, and delivery of first-generation, purified, and next-generation progenitors. First-generation stem cells are harvested from source tissue and delivered without significant processing as mixed progenitor pools. In contrast, purified biologics use a cell purification step to isolate specific cell phenotypes from source tissue, eliminating cells devoid of regenerative benefit. Next-generation stem cell therapy introduces the concept of lineage specification by either harvesting regenerative stem cells from the heart or by guiding them with a process termed cardiopoiesis to yield a pure population of progenitors guided for maximal regenerative potency. hMSC indicates human mesenchymal stem cells.
Bone Marrow Mononuclear Cells: A First-Generation Platform
The bone marrow is a readily accessible source whose use has been well established for the treatment of hematologic malignancies. Initial indication that bone marrow mononuclear cells (BMMNCs) could also be used for the treatment of heart disease was reported in preclinical models of ischemic cardiomyopathy. 14Y16 Established protocols to harvest and process marrowderived cells have expedited the evaluation of this Bfirst-generation[ cardioregenerative platform. Accordingly, BMMNCs were delivered to patients after myocardial infarction initially via intracoronary infusion ( Fig. 1) . 17Y19 Within these studies, the largest trial showing efficacy was the European Intracoronary Progenitor Cells in Acute Myocardial Infarction trial, which showed in 101 cell-treated individuals (vs. 103 placebo) an overall 5% improvement in LV ejection fraction. 19 Long-term follow-up of this trial has also indicated a mortality benefit. 20 However, when the Intracoronary Progenitor Cells in Acute Myocardial Infarction trial was compared with other trials, in particular the Autologous Stem Cell Transplantation in Acute Myocardial Infarction trial, intertrial variability was noted and primarily ascribed to differences in the number of cells delivered and the methodology implemented for cell purification. 21, 22 Recent United StatesYbased trials coordinated by the Cardiovascular Cell Therapy Network attempted to overcome this issue by carrying out trials that evaluated timing of cell delivery in tandem with imposition of rigorous uniformity in cellular processing. 23Y25 In two trials, Transplantation In Myocardial Infarction Evaluation and Late-Transplantation In Myocardial Infarction Evaluation, the impact of first-generation BMMNCs was evaluated, and these were found to have no evidence of functional benefit. 23,24,26 However, an inherent pitfall with imposing a uniformity standard in the trials carried out is that a specific protocol had to be selected. To avoid the need for a central processing facility, the Cardiovascular Cell Therapy Network coordinated trials that used a Bgood manufacturing practice in-a-box[ clinical grade manufacturing system. This approach provided significant intertrial uniformity in the cell population assessed but did not necessarily select for the cellular phenotype associated with repair. 27,28 Accordingly, a pivotal trial has now been set into motion in Europe, termed The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells on All Cause Mortality in Acute Myocardial Infarction, that will mimic the cell processing and delivery used in the Intracoronary Progenitor Cells in Acute Myocardial Infarction trial to conclusively evaluate its therapeutic utility.
Purification of Stem Cells from the Bone Marrow
With advancement in cell biology and preclinical models, individual cell populations extractable from the bone marrow have been evaluated for myocardial regeneration, identifying specific populations associated with therapeutic benefit. As such, the advent of cell purification initiated a new paradigm in regenerative medicine, moving it away from the firstgeneration mixed population therapies to a more selective approach (Fig. 1 ). Because the true basis for the benefit acquired with BMMNCs continues to be uncertain, the isolation and the use of purified cell populations afford the opportunity to evaluate therapeutic impact from a particular cell phenotype without the complexity of having to decipher the influence of competing cell populations. 29 Accordingly, two populations have been identified as having therapeutic potential and are currently under extensive trial-based investigation. The CD34 + population from the bone marrow, also termed endothelial progenitor cells, has been shown both in vitro and in preclinical studies to have a provasculogenic action on the myocardium. 30 Accordingly, there was early application of this cell population in patients with critical limb ischemia, and this was shown to impart benefit on the risk for amputation. 31,32 Furthermore, in patients with angina refractory to medical therapy, the CD34 + population has been implanted, providing initial evidence for diminished frequency of angina noted. 33Y35 This was more formally evaluated in the Adult Autologous CD34+ Stem Cells in refractory Chronic Myocardial Ischemia trial, which demonstrated evidence for improvement in exercise performance. 33 Human mesenchymal stem cells are the second cell population from the bone marrow recently evaluated for their therapeutic benefit. These cells came into consideration after initial studies suggested significant capacity for multipotent differentiation. 36Y38 The cells were formally assessed in the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis trial to ascertain whether the impact on chronic ischemic cardiomyopathy was altered when cells were delivered in autologous or allogeneic form. No difference in outcomes was noted, albeit evidence for benefit was limited. 39 The Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy clinical study evaluated firstgeneration BMMNCs vs. the purified human mesenchymal stem cell phenotype to establish their safety and provide initial evidence for efficacy. 40 With isolation of pure cell populations, the notion of identifying/ generating a reparative cell population was born.
''Next-Generation'' Stem Cell Technology
There have been two main avenues of investigation pursuing this next-generation approach. The first focuses on the harvest and the application of resident cardiac stem cells from the heart itself. This technique has been tested and reported in two separate trials using different methods for cell harvest and processing. 41, 42 The Cardiac Stem Cells In Patients with Ischaemic Cardiomyopathy trial used ckit+ cells isolated from right atrial appendage samples obtained as part of coronary artery bypass grafting. Although the final report is anticipated to be published soon, early reports of this phase I trial indicated positive efficacy signals after autologous administration of 1,000,000 cells down the coronary vessel supplying the area of transmural scar. 41, 43 Cardiac stem cells were also used in the randomized phase I Cardiosphere-Derived Autologous Stem Cells to Reverse Ventricular Dysfunction trial, 42 which isolated cells from endomyocardial biopsies obtained from the right ventricular septum. Cellular outgrowths underwent a cardiosphere processing step before being isolated as cardiosphere-derived cells and delivered, at different doses, into patients 65 days after myocardial infarction. Safety and feasibility in tandem with impact on LV scar dynamics were documented, but no impact on LV systolic function was noted. 42,44Y46 Newer studies, such as Autologous Human Cardiac-Derived Stem Cell to Treat Ischemic Cardiomyopathy, implement a hybrid approach, combining growth factors with cardiac stem cells. 47 Furthermore, the cardiosphere-derived cell population will be additionally tested in phase II studies to evaluate the efficacy of the autologous (Regenerative Cardiosphere Injection to Strengthen Dysfunctional HeartsVNCT01496209) or allogeneic (Allogeneic Heart Stem Cells To Achieve Myocardial RegenerationVNCT01458405) derivation paradigms in the treatment of ischemic heart disease.
The concept of lineage specification was introduced as an alternative to the use of myocardial tissue through cardiac biopsy, in which cells are initially obtained from an abundant and more readily accessible tissue source (e.g., bone marrow). 37, 48, 49 After isolation, cells (e.g., human mesenchymal stem cells) are subject to a guiding environment during cell expansion that specifies a cardiovascular fate in a process termed cardiopoiesis (Fig. 1) . 50Y52 In contrast to hybrid approaches that combine cell therapy with growth factors at the time of therapy, this technology preemptively guides patient-derived cells with a growth factor cocktail to prime their regenerative potential. Clinical application of this technology was recently reported in the phase II Cardiopoietic Stem Cell Therapy in Heart Failure trial, demonstrating safety and feasibility of using the cardiopoietic stem cell population in patients with chronic ischemic cardiomyopathy. Robust efficacy signals were documented with improvement in LV ejection fraction, in tandem with global benefit, such as the 6-min walk test. 48 Pivotal phase III evaluation of this newest technology is currently underway in the Congestive Heart Failure Cardiopoietic Regenerative Therapy-1 trial.
Cardiac Rehabilitation and Stem Cells
Cardiac rehabilitation integrates a systematic approach to exercise training and management of cardiovascular risk factors through regular patient evaluation, monitoring, and support of compliance and adherence to lifestyle changes. Patients who participated in cardiac rehabilitation programs have reduced all-cause and cardiac mortality as well as a mitigated recurrence of acute cardiac events and blunted need for invasive procedures. 53Y55 As stem cellYbased platforms emerge as an option in the treatment of cardiac disease, recent interest aims at establishing the putative impact of cardiac rehabilitation, specifically exercise programs in support of stem cell therapies. Stem cells are mobilized from the bone marrow, and the number of circulating cells is demonstrated to be dynamic, responding to different factors and conditions, including cytokines in the setting of infarction and comorbidities such as diabetes. 56, 57 Recent studies have evaluated the impact of exercise, with high-intensity prolonged exercise programs associated with higher number of circulating stem cells. 58, 59 To date, however, only limited data sets exist to define the precise effect of different exercise training programs on stem cell numbers and function. It has been proposed that exercise may exert a liberating action, freeing stem cells from their niche, inducing proliferation and/or differentiation, and improving homing and paracrine action by the host organ. 60, 61 Exercise modulates different signaling pathways known to affect stem cell biology. In addition to exercise, recent studies show that the number of circulating stem cells is inversely associated with cardiovascular risk factors. In this regard, patients with coronary artery disease who had a strict control of lipid profile with the use of statins displayed a higher number of circulating progenitor cells. 62, 63 Taken together, cardiac rehabilitationVin patients undergoing stem cell therapyVis of importance because it may enhance outcome not only by establishing the adequate exercise regimen but also by controlling cardiovascular risk factors.
SUMMARY
As first-and next-generation cell therapies near pivotal evaluation for therapeutic efficacy, the field of cardioregenerative medicine is poised to yield real impact on the prognosis of cardiovascular disease. Initial pioneering work established the safety and the feasibility of cell delivery into diseased patients' hearts. More recent cell purification and optimization steps have been associated with significant improvement in efficacy signals with consistent safety. 41, 42, 48 Furthermore, the appreciation for the heart's innate propensity for regeneration highlights the importance of cross-talk between the host organ and the implanted stem cells, underscoring the complexity of the regenerative response. 64, 65 Indeed, regenerative biotherapies are no longer seen as a stand-alone magic bullet but rather an inductive active ingredient that can promote a regenerative response within the injured tissue. As such, a combinatorial approach leveraging traditional approaches, such as rehabilitation, with modern regenerative strategies, such as newest stem cell biologics, provides a complementary armamentarium to reimagine clinical problems and, in so doing, usher curative therapies for cardiovascular disease. 
